{"links":{"html":"https://www.erudio.com/reports/melt-mm-nct06645678","json":"https://www.erudio.com/reports/melt-mm-nct06645678.json","markdown":"https://www.erudio.com/reports/melt-mm-nct06645678.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"melt-mm-06645678"}},"request":"https://www.erudio.com/contact?report=melt-mm-06645678"},"offer":{"cited_commentary_sources":14,"verified_hcp_statements":54,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":7,"optional":true,"price_per_verified_person_usd":15,"price_usd":105,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"melt-mm-nct06645678"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=melt-mm-06645678","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/melt-mm-nct06645678","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-01T22:37:00.802345Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":9,"no_commentary_found":0},"aspects":[{"claim_count":9,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":6,"title":"Primary endpoint: Overall response rate (ORR)"},{"claim_count":11,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":7,"title":"Secondary endpoints"},{"claim_count":9,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":5,"title":"Population and setting"},{"claim_count":8,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":7,"title":"The comparison"},{"claim_count":10,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":9,"title":"Safety and tolerability"},{"claim_count":12,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":8,"title":"Design and conduct"},{"claim_count":20,"coverage":"discussed","id":"A1","source_count":6,"title":"T-cell fitness, resistance and conditional sequencing hypotheses"},{"claim_count":5,"coverage":"discussed","id":"A2","source_count":3,"title":"Higher response benchmarks, de-escalation and cure-oriented interpretation"},{"claim_count":5,"coverage":"discussed","id":"A3","source_count":3,"title":"Indian practice impact, delivery burden and patient research access"}],"counts":{"cited_sources":15,"claims_by_expression_type":{"comparison":5,"interpretation":19,"opinion":11,"primary_context":1,"question":4,"restatement":14},"claims_by_kind":{"protocol_statement":1,"source_observation":53},"clinician_statements":15,"evidence_units":29,"findings":6,"people_cited":10,"people_identity_verified":7,"people_total":10,"screened_sources":25,"verified_claims":54},"findings_index":[{"id":"F1","structure":{"claims":15,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":7,"views":6},"has_counterview":true,"limitations":3,"links":{"context":4,"support":16},"ma_question":true,"named_voices":5,"passages":9,"sources":6,"sources_by_kind":{"commentary":3,"media":3}},"title":"The response signal is “striking,” but its durability and generalizability remain open"},{"id":"F2","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":1,"views":6},"has_counterview":true,"limitations":4,"links":{"context":1,"support":8},"ma_question":true,"named_voices":5,"passages":8,"sources":7,"sources_by_kind":{"commentary":4,"media":3}},"title":"Manageable CRS is not a judgment that the whole combination is low burden"},{"id":"F3","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":4},"has_counterview":true,"limitations":4,"links":{"context":1,"support":8},"ma_question":true,"named_voices":2,"passages":6,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Deep MRD responses prompt a higher benchmark—not a cure or treatment-free conclusion"},{"id":"F4","structure":{"claims":23,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":7,"views":13},"has_counterview":false,"limitations":4,"links":{"context":1,"support":24},"ma_question":true,"named_voices":5,"passages":13,"sources":8,"sources_by_kind":{"commentary":3,"media":5}},"title":"T-cell reconditioning is the rationale; extending durability without switching remains a question"},{"id":"F5","structure":{"claims":4,"claims_by_group":{"comparisons":4,"experience":0,"questions":0,"restated":0,"views":0},"has_counterview":false,"limitations":4,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":3,"sources":3,"sources_by_kind":{"commentary":1,"media":2}},"title":"Alternative CELMoD partners are discussed through activity consistency and a possible safety advantage"},{"id":"F6","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":0,"views":3},"has_counterview":false,"limitations":4,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":4,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Practice impact depends on safe delivery, affordability and research access"}],"medical_affairs_question":"How much durable benefit does adding mezigdomide provide, for whom, and at what safety and delivery burden?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Response depth attracts enthusiasm; sustained benefit remains the unresolved question"},{"id":"section-2","level":2,"title":"Safety discussion separates low-grade CRS from infection, marrow and hepatic burden"},{"id":"section-3","level":2,"title":"MRD ceilings raise the standard for durability and treatment-duration claims"},{"id":"section-4","level":2,"title":"Reconditioning T cells is a rationale, not yet a validated rescue strategy"},{"id":"section-5","level":2,"title":"Alternative partners are hypotheses and descriptive benchmarks, not demonstrated winners"},{"id":"section-6","level":2,"title":"Local delivery requirements and research-access questions"},{"id":"section-7","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, single group, phase1, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":8},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2}],"id":"T1","label":"Primary endpoint: Overall response rate (ORR)"},{"findings":[{"id":"F1","shared_claims":8},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":5},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":5},{"id":"F5","shared_claims":4}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":8},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":2}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":8},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":2}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-01T22:37:00.802345Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-01T22:49:43Z","record_hash":"7dee04084761a47255bb04d8ddb1f17408de655390b5476765aa2fc54ac928d3","release_hash":"8f281785edd017e4e4074854a5956b172b0360d0fdd3dea8fa1319761f3fac4d","report_id":"erudio-nct06645678","run_id":"96ed8038-48b2-4792-8f50-945e58059b0d","schema_version":"5.0","slug":"melt-mm-06645678","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Clinician commentary on MELT-MM in the sources reviewed for this edition leads to one open question: How much durable benefit does adding mezigdomide provide, for whom, and at what safety and delivery burden? Its leading findings: (1) the response signal is “striking,” but its durability and generalizability remain open. (2) manageable CRS is not a judgment that the whole combination is low burden. (3) deep MRD responses prompt a higher benchmark—not a cure or treatment-free conclusion. 3 more findings follow. 25 sources screened, 15 cited; not all HCPs or all public discussion.","meta_description":"25 sources screened · 54 verified statements (15 from clinicians verified by NPI or staff page) from 15 sources · 6 findings. Updated Nov 1, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-11-01T22:49:43Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":25},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","13 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The report describes the sources reviewed for this edition, not the prevalence of views among HCPs. Reposts and overlapping media accounts are not independent clinician endorsements.","Some potentially relevant passages were not fully assessed for additional views. Discussions using unnamed references or different terminology may also be missing, so coverage is not exhaustive.","No standalone protocol, exact-trial results publication or exact mezigdomide label was available in the sources reviewed. Registry information describes planned methods and cannot verify the reported clinical outcomes.","Small cohorts, evaluability exclusions and different follow-up cutoffs prevent pooling of the response and safety accounts or inference of changing efficacy over time.","Some spoken passages remain unidentified despite names in publisher descriptions. An unclear response-category transcription and an incompletely transcribed marker have not been resolved by inference.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The same-combination safety post by a speaker does not name MELT-MM. It informs the clinical safety question but is not treated as a separately confirmed result of this trial."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":1,"publication":0,"registry":1,"regulatory":0,"x_thread":7,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":14,"methods":1},"count":15,"evidence_window":{"end":"2026-10-25","start":"2025-12-15"},"retrieval_snapshot":"2026-11-01T22:12:11.670805Z","timeline":[{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W15"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W21"},{"count":6,"week":"2026-W39"},{"count":2,"week":"2026-W40"},{"count":1,"week":"2026-W43"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06645678:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06645678:context","quote_policy":"short_quote_link_out"},{"id":"openfda:aa044060-5b4b-4692-bf0f-9a50e140b10e:20260514","quote_policy":"short_quote_link_out"},{"id":"openfda:11f10a47-1c42-40e4-89d8-bb000fef497c:20260909","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-vfwxbyybcmuhaderu7owb6sf-3mw6sdfuj7l26","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7510770836698517504","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:a8e3a6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056453282223272207:791688d6-d9c8-42a5-8ded-4bf1573ceb57","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2085702038172979528:090c271c-3eaf-4e98-9c67-b0b6e8992a56","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102744573697253578:fc077adb-acc4-4d90-8e3c-4758b471c501","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102763714243948742:5ecda98a-f74f-4468-b14a-c879d29e6813","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102810843968639226:f8b19917-38dd-4268-9024-7d78f3b5c7e2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102842912761606253:5546e956-9db2-4ba1-9c8d-c89dcfe89ff1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102848821726498968:50b2936b-3d11-4f83-87ee-a8ec0a1d203b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102880499957977428:34138571-917d-4393-bb65-f5028b9375c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103309206224851006:bec2a85d-e164-4b5b-8ed7-a0216a1ee6a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103788258346066275:5c5996d3-12b2-4a64-ae34-b020d3b61493","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103941451407356025:c2cdf487-b916-4f9b-ad9f-9411a4031c70","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104232039981490681:2db85646-d4b4-412e-85aa-5a3fe07e3c49","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104252785864921167:948934b9-a189-46b8-ba54-6cce8463a95f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104262286512697854:0a05fb6a-a158-4189-9167-42a37ecc647a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104894600976494739:3365d39e-b830-4e60-ab2a-02f4113a8bf0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105001864500789688:1659dd97-7ed7-40cc-bce9-9845f4ee017c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114145885315559931:227ff7f0-bac9-4c46-8cd7-3b4c18e54fcd","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:0PNQqQBwaIA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:BMbhiuKavaI","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:NajdQIMfXws","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:WqRT5HfhVeY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:lkCHfEIDCM4","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":1,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":17,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":25},"count":25,"evidence_window":{"end":"2026-10-25","start":"2025-12-15"},"retrieval_snapshot":"2026-11-01T22:12:11.670805Z","timeline":[{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W15"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W21"},{"count":1,"week":"2026-W32"},{"count":15,"week":"2026-W39"},{"count":3,"week":"2026-W40"},{"count":1,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: elranatamab","status":"unmapped"},{"reason":"Unmapped registry intervention: mezigdomide","status":"unmapped"},{"brand_names":["Decadron","Dexacen-4","Dexone","Hemady","Hexadrol","Taperdex"],"label":"dexamethasone","slug":"dexamethasone"}],"indications":[{"reason":"Unmapped registry condition: Relapsed Refractory Multiple Myeloma (RRMM)","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"MELT-MM","aliases":["MELT-MM","Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma","Phase I/II Study of Mezigdomide and Elranatamab for Relapsed/Refractory Multiple Myeloma Patients"],"brief_title":"Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Relapsed Refractory Multiple Myeloma (RRMM)"],"display_condition":"relapsed/refractory multiple myeloma","display_interventions":[["mezigdomide","elranatamab","dexamethasone"]],"enrollment":{"count":75,"type":"ESTIMATED"},"interventions":[{"name":"Elranatamab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Mezigdomide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Dexamethasone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06645678","official_title":"Phase I/II Study of Mezigdomide and Elranatamab for Relapsed/Refractory Multiple Myeloma Patients","overall_status":"RECRUITING","phase":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-10-01","type":"ESTIMATED"},"primary_endpoints":[{"description":"Percentage of subjects who achieve best response of partial response (PR) or better according to the IMWG Uniform Response Criteria for Multiple Myeloma","measure":"Overall response rate (ORR)","timeFrame":"From C1D1 to confirmed PD, lost to follow-up, or death (whichever occurs first), assessed up to 24 months"}],"registered_date":{"date":"2024-10-17","type":"ACTUAL"},"registry_last_updated":"2025-12-03","registry_url":"https://clinicaltrials.gov/study/NCT06645678","short_name":"MELT-MM","short_name_basis":"registry_acronym","sponsor":"YOUNGIL KOH","start_date":{"date":"2024-11-26","type":"ACTUAL"},"study_design":"interventional, na, single group, phase1, phase2","study_ids":[{"id":"H-2410-028-1576","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}